Dr. Kelly Chillari is a pharmacist who is specialized in Oncology in Columbia, Missouri. Patients can reach her at 800 Hospital Dr, Columbia or contact her on 573-814-6000. Active license number of Dr. Kelly Chillari is 28RI03717000 for Oncology in New Jersey. Dr. Kelly Chillari is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Kelly Chillari speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Kelly Chillari
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
800 Hospital Dr, Columbia, Missouri, 65201-5275
Phone:
573-814-6000
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Kelly Chillari are as mentioned below.
NPI Number:
1871949602
NPI Enumeration Date:
11 May, 2016
NPI Last Update On:
12 Oct, 2024
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Kelly Chillari are as mentioned below.
Specialization
License Number
State
Status
Oncology
28RI03717000
New Jersey
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
Po Box 2429, Smyrna, Tennessee
Zip:
37167-1719
Phone Number:
615-355-3451
Fax Number:
--
Patients can reach Dr. Kelly Chillari at 800 Hospital Dr, Columbia, Missouri or can call on phone at 573-814-6000.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.